Affiliation:
1. Department of Biostatistics Yale School of Public Health New Haven Connecticut
2. Global Biometrics & Data Management Pfizer Inc New York New York USA
Abstract
Among clinical trialists, there has been a growing interest in using external data to improve decision‐making and accelerate drug development in randomized clinical trials (RCTs). Here we propose a novel approach that combines the propensity score weighting (PW) and the multi‐source exchangeability modelling (MEM) approaches to augment the control arm of a RCT in the rare disease setting. First, propensity score weighting is used to construct weighted external controls that have similar observed pre‐treatment characteristics as the current trial population. Next, the MEM approach evaluates the similarity in outcome distributions between the weighted external controls and the concurrent control arm. The amount of external data we borrow is determined by the similarities in pretreatment characteristics and outcome distributions. The proposed approach can be applied to binary, continuous and count data. We evaluate the performance of the proposed PW‐MEM method and several competing approaches based on simulation and re‐sampling studies. Our results show that the PW‐MEM approach improves the precision of treatment effect estimates while reducing the biases associated with borrowing data from external sources.
Funder
National Cancer Institute
National Institute of Dental and Craniofacial Research
Reference37 articles.
1. US Food and Drug Administration.Rare diseases: natural history studies for drug development guidance for industry.https://www.fda.gov/media/122425/download2019.
2. Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions
3. Advancing innovative clinical trials to efficiently deliver medicines to patients
4. Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness
5. US Food and Drug Administration.Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products.https://www.fda.gov/media/164960/download